511 |
I-LOVE-IT: A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic and 1-Year Clinical Follow-Up Results |
Runlin Gao |
Jul. 21. 09 |
510 |
Comparison of DES versus BMS in Real World Registries |
Gregg W. Stone |
Jul. 21. 09 |
509 |
DES Pathobiology: Insights from Assessment of Endothelial Integrity and Function |
Renu Virmani |
Jul. 21. 09 |
508 |
The Clinical Spectrum of DES Thrombosis: Multifactorial Causes, Clinical Presentations, and Recommended Treatment Strategies |
Ron Waksman |
Jul. 21. 09 |
507 |
Future DES: What¡¯s New and Innovative in Drugs, Carrier Vehicles, and Stent Platforms |
Alexandre Abizaid |
Jul. 21. 09 |
506 |
The Changing Landscape of DES Use Patterns: Finally Stabilizing or Still in Transition? |
Martin Bert Leon |
Jul. 21. 09 |
505 |
CABG Remains an Excellent Selection for All Patients ! |
David Paul Taggart |
Jul. 21. 09 |
504 |
Time to Move into Stenting in All Patients ! |
Patrick W. Serruys |
Jul. 21. 09 |
503 |
Why Even Favorable One-Year Data From HORIZONS Shouldn¡¯t Compel DES Usage in AMI |
Renu Virmani |
Jun. 29. 09 |
502 |
New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us? |
Gregg W. Stone |
Jun. 29. 09 |